The DOI matches its Crossref record; 106 of the 108 references it cites were found in a registry or an index; 151 of the 237 sources its claims cite were checked for support.
Off-target effects in CRISPR/Cas9 gene editing
Open accessAbstract
Gene editing stands for the methods to precisely make changes to a specific nucleic acid sequence. With the recent development of the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system, gene editing has become efficient, convenient and programmable, leading to promising translational studies and clinical trials for both genetic and non-genetic diseases. A major concern in the applications of the CRISPR/Cas9 system is about its off-target effects, namely the deposition of unexpected, unwanted, or even adverse alterations to the genome. To date, many methods have been developed to nominate or detect the off-target sites of CRISPR/Cas9, which laid the basis for the successful upgrades of CRISPR/Cas9 derivatives with enhanced precision. In this review, we summarize these technological advancements and discuss about the current challenges in the management of off-target effects for future gene therapy.
Overview
CoChat Summary
TL;DR
This review summarizes methods for predicting and detecting CRISPR/Cas9 off-target effects and strategies for improving editing specificity. It emphasizes persistent trade-offs between accuracy and sensitivity and the difficulty of assessing off-target effects in vivo and in patients.
Key findings
- Off-target effects remain a major challenge for CRISPR/Cas9; Cas9 tolerates up to 3 mismatches between sgRNA and genomic DNA, and sgRNA-independent off-target effects also occur.
- In silico tools are convenient but biased toward sgRNA-dependent off-target effects and require experimental validation; examples include CasOT, Cas-OFFinder, FlashFry, Crisflash, MIT, CCTop, CROP-IT, CFD, DeepCRISPR, and Elevation.
- Experimental detection methods vary widely: Digenome-seq detects indels at 0.1% frequency or lower but needs ∼400–500 million reads for the human genome; SITE-seq needs ∼0.62–2.46 million reads but only 10% of positive hits were validated by targeted sequencing; CIRCLE-seq needs ∼4–5 million reads but has a high false positive rate; GUIDE-seq detects indel frequencies as low as 0.03% but captures only 30%–50% of all DSBs.
- Specificity strategies include high-fidelity Cas9 variants (eSpCas9, SpCas9-HF1, hypaCas9, evoCas9), sgRNA length/chemical modification, DSB-independent base editors, and delivery methods such as RNP electroporation and LNPs; evoCas9, SpCas9-HF1, and eSpCas9 reduced off-target sites by 98.7%, 95.4%, and 94.1%, respectively, in one comparison.
Methods
- This is a narrative review, not a primary experimental study; no original sample, dataset, or systematic meta-analysis is described.
- It synthesizes in silico prediction tools, cell-free, cell culture-based, and in vivo off-target detection methods, plus strategies to reduce off-target effects.
- Main analysis is qualitative comparison of advantages and disadvantages, organized in Tables 1 and 2 and supported by cited literature.
Limitations
- The paper states that limitations remain in balancing accuracy versus sensitivity of off-target detection techniques, and that direct assessment of off-target effects in vivo and in patients is particularly challenging.
- It notes that in silico predictions are biased toward sgRNA-dependent off-target effects and need experimental validation, and that many experimental methods have limitations such as high cost, high sequencing coverage, low sensitivity, false positives, false negatives, or dependence on chromatin accessibility.
- Evident from the text: as a review, it provides no new experimental data, and it states there is currently no standardized approach to confirm the sensitivity of Discover-seq.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
78 Valid · 10 Not valid · 21 Not checked · 25 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Similarly, the Elevation tool also includes DNA accessibility information to predict potential off-target sites (Listgarten et al., 2018).”
§ Off-target effects in CRISPR/Cas9 gene editing > 2 In silico prediction
What the sources say
- Disputedcites Listgarten et al., 2018 sourceExperimental — accuracy not yet measured
The Results section, “Predicting with chromatin accessibility” (page not provided), says the authors tested DNase I accessibility features but decided not to include them in the final deployed Elevation model because the results were inconclusive. Thus, the paper says the tool does not include the information the claim attributes to it. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“A primary limitation of GUIDE-seq is relevant to the low delivery efficiency of dsODNs into cells, which results in detection of only 30%–50% of all the DSBs (Tsai et al., 2015; Pan et al., 2022).”
§ Off-target effects in CRISPR/Cas9 gene editing > 3 Experimental detection > 3.2 Cell culture-based methods
What the sources say
- Disputedcites Tsai et al., 2015 sourceExperimental — accuracy not yet measured
The Results (Overview of the GUIDE-Seq method; page unavailable) report robust dsODN integration, at rates two- to three-fold lower than indel frequencies at the tested sites—not detection of 30%–50% of all DSBs. The Discussion (page unavailable) describes dsODN integration as very efficient and reports detection of 38 of 40 previously identified off-target sites, contrary to the claimed primary limitation. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
- Partly supportedcites Pan et al., 2022 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says GUIDE-seq relies on inserting double-stranded DNA at double-strand breaks, and the Results section on SURRO-seq validation likewise describes insertion of a double-stranded oligonucleotide. Neither passage says that delivery into cells is inefficient or that GUIDE-seq detects only 30%–50% of DSBs; searches for those terms found no such estimate in our copy. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“| Delivery methods improvement | Application in cell culture [89–94] | RNP electroporation: Rapid transfection and turnover | Eliminate off-target effects |”
§ Off-target effects in CRISPR/Cas9 gene editing > 4 Strategies to reduce off-target effects > 4.1 Cas9 improvement
What the sources say
- Not checked — no full text of the sourcecites [89] Wang, 2021, Detection of CRISPR/Cas9-Generated off-target effect by integration-defective lentiviral vector, Methods Mol. Biol. source
- Disputedcites [90] Wienert, 2019, Unbiased detection of CRISPR off-targets in vivo using DISCOVER-Seq, Science sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) reports editing patient-derived iPSCs with HiFi-Cas9 RNPs and detecting two off-targets with the wild-type guide. That contradicts the claim that RNP delivery eliminates off-target effects; the passage does not specify electroporation or rapid turnover. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [91] Willyard, 2017, The epigenome editors: How tools such as CRISPR offer new details about epigenetics, Nat. Med. source
- Could not verifycites [92] Witzigmann, 2020, Lipid nanoparticle technology for therapeutic gene regulation in the liver, Adv. Drug Deliv. Rev. sourceExperimental — accuracy not yet measured
The ‘mRNA for gene expression and genome editing’ section describes lipid-nanoparticle delivery of Cas9-encoding mRNA with sgRNA, including results in mice. Searches for RNP electroporation, rapid turnover, and off-target effects found no passage addressing whether electroporation in cell culture eliminates off-target effects. The available passages therefore do not verify the claim. (LLM, conf=0.74)
- Could not verifycites [93] Wu, 2014, Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells, Nat. Biotechnol. sourceExperimental — accuracy not yet measured
The Online Methods (Cell culture) say transfections used Lipofectamine 2000, not RNP electroporation. The Results (One of 295 off-target sites is mutated above background) report an off-target mutation, but do not test whether RNP electroporation eliminates off-target effects. Searches for RNP electroporation and ribonucleoprotein delivery found no passage addressing that claim. (LLM, conf=0.76)
- Could not verifycites [94] Wu, 2022, Genome-wide analyses of PAM-relaxed Cas9 genome editors reveal substantial off-target effects by ABE8e in rice, Plant Biotechnol. J. sourceExperimental — accuracy not yet measured
The Experimental procedures section describes Agrobacterium-mediated transformation of rice calli, not RNP electroporation in cell culture. The Results report off-target mutations from the rice editors studied, but do not test whether RNP electroporation eliminates them. Searches for RNP delivery and electroporation found no passage addressing that claim. (LLM, conf=0.77)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Cas-OFFinder is more widely applicated due to its high tolerance of sgRNA length, PAM types, and the number of mismatches or bulges (Bae et al., 2014).”
§ Off-target effects in CRISPR/Cas9 gene editing > 2 In silico prediction
What the sources say
- Partly supportedcites Bae et al., 2014 sourceExperimental — accuracy not yet measured
The Results and Discussion section reports searches using 20-bp and 24-bp guide-matching sequences and different PAMs; its conclusion says Cas-OFFinder does not limit the number of mismatched bases. The Methods section describes counting mismatches, but no passage establishes that the tool tolerates bulges. That part of the claim is unsupported by this copy. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although CRISPR/Cas systems exhibit tremendous potential in translational medicine, off-target effects remain a major challenge (Fu et al., 2013; Hsu et al., 2013; Pacesa et al., 2022).”
§ Off-target effects in CRISPR/Cas9 gene editing > 1 Introduction
What the sources say
- Not matchedcites Fu et al., 2013
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites Hsu et al., 2013 sourceExperimental — accuracy not yet measured
The paper’s Abstract (page unavailable) documents off-target editing in human cells and describes ways to minimize it, supporting the claim that off-target effects are a challenge for Cas9 genome editing. It does not specifically assess translational medicine or establish how major that challenge is in clinical use. (LLM, conf=0.81)
- Supportedcites Pacesa et al., 2022 source
The Introduction says that off-target activity of SpCas9 and other Cas9 enzymes presents a safety concern for therapeutic applications. The Discussion also links improved off-target prediction to safer therapeutic use, supporting the cited background claim. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
82 more claims · 52 with their cited sources checked
Create a free account to see all 134 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 33
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Off-target effects are unintended genomic modifications occur when guide RNA (gRNA) binds to sequences similar to, but not identical with, the intended target, potentially resulting in undesirable DNA cleavage and mutations (Guo et al., 2023; Lopes and Prasad, 2024; Garrigues et al., 2023).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Guo et al., 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, recent studies have shown that Cas9 tolerates up to three mismatches between the gRNA and genomic DNA, which increases the chances of off-target effects in regions with higher GC content.”
From Hybrid Neural Networks for Off-Target Prediction in Gene Editing: Integrating Sequence and Biophysical Features (2025) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although CRISPR/Cas9 introduces targeted mutations, it actually supports the maintenance of clonal fidelity by offering precise and controlled gene editing, unlike the random and widespread genetic alterations associated with somaclonal variation [178].”
From Somaclonal Variation and Clonal Fidelity in Commercial Micropropagation: Challenges and Perspectives (2025) · cites this paper as [178]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Off-target effects in CRISPR/Cas9 gene editing > 2 In silico prediction
“| In silico prediction | Alignment based models | CasOT [21] | Adjustable in PAM sequence and the mismatch number (at most 6) | Conveniently accessable via internet | Biased toward sgRNA-dependent off-target effects; results need experimental validation |”
§ Off-target effects in CRISPR/Cas9 gene editing > References
“95. Xiao A. Cheng Z. Kong L. Zhu Z. Lin S. Gao G. (2014). CasOT: A genome-wide cas9/gRNA off-target searching tool.”
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116 · cited 11×
“Cas-OFFinder is more widely applicated due to its high tolerance of sgRNA length, PAM types, and the number of mismatches or bulges (Bae et al., 2014).”
BackgroundInfluentialMultiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339 · cited 11×
“Cas-OFFinder is more widely applicated due to its high tolerance of sgRNA length, PAM types, and the number of mismatches or bulges (Bae et al., 2014).”
BackgroundInfluentialProgrammable editing of a target base in genomic DNA without double-stranded DNA cleavage
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437 · cited 1×
“ABE catalyzes the editing from adenine to guanine and CBE converts cytosine to thymine (Komor et al., 2016; Gaudelli et al., 2017; Wu et al., 2022).”
BackgroundDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741 · cited 5×
“The off-target sites are often sgRNA-dependent, since Cas9 is known to tolerate up to 3 mismatches between sgRNA and genomic DNA (Fu et al., 2013; Hsu et al., 2013; Wang et al., 2016a).”
BackgroundInfluentialOptimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench, J. G., Fusi, N., Sullender, M., Hegde, M., Vaimberg, E. W., Donovan, K. F., Smith, I., Tothova, Z., Wilen, C., Orchard, R., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3437 · Cited by 4,637 · cited 2×
“The CFD algorithm is derived from a CRISPR/Cas9 genetic screen experiment that assessed the off-target effects of thousands of sgRNAs (Doench et al., 2016).”
BackgroundMethodProgrammable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184 · cited 1×
“ABE catalyzes the editing from adenine to guanine and CBE converts cytosine to thymine (Komor et al., 2016; Gaudelli et al., 2017; Wu et al., 2022).”
BackgroundHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292 · cited 2×
“The off-target sites are often sgRNA-dependent, since Cas9 is known to tolerate up to 3 mismatches between sgRNA and genomic DNA (Fu et al., 2013; Hsu et al., 2013; Wang et al., 2016a).”
BackgroundHigh-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects
Kleinstiver, B. P., Pattanayak, V., Prew, M. S., Tsai, S. Q., Nguyen, N. T., Zheng, Z., & Joung, J. K. (2016) · Nature · doi:10.1038/nature16526 · Cited by 2,673
Rationally engineered Cas9 nucleases with improved specificity
Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., & Zhang, F. (2016) · Science · doi:10.1126/science.aad5227 · Cited by 2,414 · cited 8×
“This idea led to the rational design of SpCas9 mutants such as enhanced SpCas9 (eSpCas9) and SpCas9-HF1 (HF1 for high-fidelity variant #1).”
BackgroundInfluentialBae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339 · cited 1×
“Cas-OFFinder is more widely applicated due to its high tolerance of sgRNA length, PAM types, and the number of mismatches or bulges (Bae et al., 2014).”
Background
Cited by
Lu, P., Ruan, D., Huang, M., Tian, M., Zhu, K., Gan, Z., & Xiao, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01852-x · Cited by 667
Recent advances of CRISPR-based genome editing for enhancing staple crops
Chen, F., Chen, L., Yan, Z., Xu, J., Feng, L., He, N., Guo, M., Zhao, J., Chen, Z., Chen, H., et al. (2024) · Frontiers in Plant Science · doi:10.3389/fpls.2024.1478398 · Cited by 179
“High-fi delity Cas9 variants, such as eSpCas9, SpCas9-HF1 and FrCas9, have been engineered to enhance precision by reducing nonspeci fi c DNA interactions (Guo et al., 2023; He et al., 2024).”
BackgroundAljabali, A. A. A., El‐Tanani, M., & Tambuwala, M. M. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105338 · Cited by 186
Dias, J., García, J., Agliardi, G., & Roddie, C. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101250 · Cited by 129
Recent advancements in reducing the off-target effect of CRISPR/Cas9 genome editing
Asmamaw Mengstie, M., Teshome Azezew, M., Asmamaw Dejenie, T., Teshome, A. A., Tadele Admasu, F., Behaile Teklemariam, A., Tilahun Mulu, A., Mekonnen Agidew, M., Adugna, D. G., Geremew, H., et al. (2024) · Biologics: Targets and Therapy · doi:10.2147/btt.s429411 · Cited by 91
“14 Studies have also shown that chemical modifications at particular locations in the guide sequences can significantly increase the specificity and flexibility of CRISPR-Cas systems for the precise editing of genes.”
Background
Metadata
- Authors
- Guo, C., Ma, X., Gao, F., & Guo, Y.
- Affiliations
- Peking University (CN)
- Capital Medical University (CN)
- Corresponding author
- Gao, Fei
- Guo, Yuxuan
- Venue
- Frontiers in Bioengineering and Biotechnology
- Publisher
- Frontiers Media SA
- Published
- 2023-03-09
- Volume
- 11
- Pages
- 1143157-1143157
- ISSN
- 2296-4185 (ISSN-L)
- PMC
- PMC10034092
- OpenAlex
- W4323666400
- Cited by
- 704
- References
- 108
- Citations by year
- 2026: 225 · 2025: 290 · 2024: 154 · 2023: 35
- FWCI
- 17.24
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Bioengineering and Biotechnology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82100349, 82222006, 32100660, 82170367)
- Beijing Nova Program (Z211100002121003, 20220484205)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- CRISPR/Cas9, off-target effects, genome editing, gene therapy, Cas9 variants
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Off-target effects in CRISPR/Cas9 gene editing. https://app.cochat.ai/papers/10.3389/fbioe.2023.1143157
- The paper
- Guo, C., Ma, X., Gao, F., & Guo, Y. (2023). Off-target effects in CRISPR/Cas9 gene editing. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2023.1143157
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
